Business Context and Reporting Period
This Form 8-K was filed by Lion Biotechnologies, Inc. (not IOVANCE BIOTHERAPEUTICS, INC.) on November 23, 2016. The report details the entry into a Material Definitive Agreement with WuXi AppTec, Inc., a global contract research organization, to support the Company's autologous cell therapy products.
Key Financial Metrics and Agreements
The filing outlines specific financial commitments under two Statements of Work (SOW) within the Manufacturing Services Agreement:
- SOW 1 Fee: $2.5 million for the use of one cGMP manufacturing suite during the next year, including personnel fees.
- SOW 2 Fee: $5.85 million for the establishment and operation of a second, dedicated late-stage/commercial cGMP suite during the next year, including personnel fees.
- Additional Costs: The Company will pay additional fees based on testing, analysis, raw materials, and production services. Equipment purchases for the second suite are also required in addition to the stated fees.
- Total Committed Fees (Year 1): $8.35 million (excluding variable costs and equipment).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a current report regarding a specific agreement rather than a periodic financial statement.
Material Changes and Agreement Terms
The primary material change is the formalization of manufacturing capabilities through WuXi AppTec. Key terms include:
- Term: The Agreement has a three-year term.
- Termination by Company: Requires 30 days' written notice; the Company remains liable for fees owed under outstanding SOWs and termination fees.
- Termination by WuXi AppTec: Requires 180 days' written notice; the Agreement remains in effect for outstanding SOWs.
- Process Transfer: The Company agreed to transfer its current tumor infiltrating lymphocyte manufacturing process to the new dedicated suite.
Outlook, Risks, and Management Commentary
Management indicates plans to utilize these facilities for commercial manufacture. The filing includes a standard Forward-Looking Statements disclaimer, noting that actual results may differ materially due to risks such as inaccurate assumptions regarding manufacturing plans, costs, and development programs. The Company does not assume an obligation to update these statements.
Investor Verification Checklist
- Verify the total capital requirements including the $8.35 million in committed fees plus variable costs and equipment purchases.
- Confirm the Company's current cash position to ensure it can fund the $2.5 million and $5.85 million payments within the next year.
- Review the specific termination fee clauses to understand potential liabilities if the agreement is ended early.
- Monitor the timeline for the transfer of the tumor infiltrating lymphocyte manufacturing process to WuXi AppTec.